AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10660238
Drug: PCEA solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA solution of 0.0625% bupivacaine and fentanyl 2 microg/mL (4 mL demand bolus, 15 min lockout) without clonidine (group BF)
Trial: 2871945
Drug: MPA (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA (500 mg b.i.d. for 6 months)
Trial: 26274985
Drug: Parenteral nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral nimodipine (1-2 mg/hr) and hydroxyethyl starch (hematocrit 30%-35%) from the day before surgery until the 7th postoperative day
Trial: 26274985
Drug: Parenteral nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral nimodipine (1-2 mg/hr) and hydroxyethyl starch (hematocrit 30%-35%)
Trial: 19023152
Drug: Low-dose abciximab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose abciximab (0.20 mg/kg bolus followed by 12-h infusion)
Trial: 19023152
Drug: High-dose abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose abciximab (0.25 mg/kg bolus followed by 12-h infusion)
Trial: 19023152
Drug: Placebo (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (bolus and infusion of placebo)
Trial: 21046232
Drug: No aromatase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aromatase inhibitors (no AIs)
Trial: 19081397
Drug: 300-mg loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg loading dose of clopidogrel
Trial: 16390629
Drug: Micronutrient sprinkles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient sprinkles containing 30 mg Fe/day
Trial: 11276275
Drug: Potent pancreatic
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent pancreatic enzyme supplement (4 capsules with meals, 2 with snacks; lipase 10,000 USP units, protease 37,500 units, amylase 33,200 units)
Trial: 7933491
Drug: Ephedrine (EP)
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine (EP) 0.15 mg.kg‐1
Trial: 27625146
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg, local submucosal injection)
Trial: 27625146
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution, local submucosal injection)
Trial: 20940690
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with carnitine, acetyl carnitine, L-arginine and ginseng
Trial: 11305547
Drug: Metronidazole 2
RxNorm normalized name: metronidazole 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 2 g suppository
Trial: 9369820
Drug: Once-daily gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily gentamicin (4 mg/kg IV every 24 hours) with twice-daily clindamycin (1200 mg IV every 12 hours)
Trial: 9369820
Drug: Thrice-daily gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily gentamicin (1.33 mg/kg IV every 8 hours) with clindamycin (800 mg IV every 8 hours)
Trial: 9369820
Drug: Once-daily gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily gentamicin with twice-daily clindamycin
Trial: 9369820
Drug: Thrice-daily gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily gentamicin with clindamycin
Trial: 1578946
Drug: Monthly myelosuppressive
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly myelosuppressive maintenance for 3 years after initial TAD treatment in the 1981 study.
Trial: 6738937
Drug: Long-acting prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting prostaglandin suppository (9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2)
Trial: 31478290
Drug: Cuminum cyminum
RxNorm normalized name: CUMINUM CYMINUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuminum cyminum L. essential oil (CuEO) 75 mg, thrice daily for 8 weeks
Trial: 31478290
Drug: Placebo soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo soft gel, thrice daily for 8 weeks
Trial: 25546488
Drug: Multidisciplinary group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary group-based rehabilitation program plus oral medication
Trial: 19246733
Drug: Cephradine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephradine (500 mg)
Trial: 19246733
Drug: Captopril and
RxNorm normalized name: captopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril and Cephradine co-administration
Trial: 10505743
Drug: IFN therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN therapy
Trial: 8726600
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with lovastatin 20 mg/day and niacin 500 mg 3 times/day
Trial: 6465160
Drug: Aspirin (2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (2,400 and 3,900 mg/day)
Trial: 7234826
Drug: Ibuprofen (2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (2,400 mg/day)
Trial: 6465160
Drug: Ibuprofen (1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1,600 mg/day for three days)
Trial: 6465160
Drug: Ibuprofen (4,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (4,800 mg/day)
Trial: 6465160
Drug: Naproxen, tolmetin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen, tolmetin sodium, indomethacin (larger doses)
Trial: 6465160
Drug: Placebo, pro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, pro drugs, enteric-coated aspirin
Trial: 24769600
Drug: Procarbazine, lomustine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procarbazine, lomustine, and vincristine (PCV) chemotherapy combined with standard radiation therapy (RT)
Trial: 24769600
Drug: Standard course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard course of radiation therapy (RT)
Trial: 20377116
Drug: Levocetirizine 5
RxNorm normalized name: Levocetirizine 5mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine 5 mg once daily for 2 weeks
Trial: 8923037
Drug: Anticarcinogenic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticarcinogenic agent (specific agent not mentioned)
Trial: 1909810
Drug: Oral natural
RxNorm normalized name: Nature-Throid Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral natural micronized progesterone
Trial: 22466821
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume (V(T) 5 ml kg(‐1)) with high PEEP
Trial: 22466821
Drug: Larger tidal
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger tidal volume (V(T) 8 ml kg(‐1)) with low PEEP
Trial: 20880345
Drug: Ezetimibe/simvastatin (E/S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin (E/S) + extended-release niacin (N)
Trial: 10515518
Drug: Delayed-treatment group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-treatment group (Control)
Trial: 8746601
Drug: Triglycerides, HDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglycerides, HDL cholesterol, and insulin variables
Trial: 2042788
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) infusion (7 mg/kg bolus followed by 10 mg/kg/h continuous infusion)
Trial: 2042788
Drug: Concurrent MgSO4
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concurrent MgSO4 and epinephrine administration
Trial: 7266894
Drug: E.N.L. protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E.N.L. protocol (erythromycin + neomycin + 600 mg lincomycin 1 hr prior to surgery)
Trial: 31552526
Drug: Omalizumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (150 mg) administered as a single subcutaneous injection 2 weeks postoperatively.
Trial: 31552526
Drug: Intranasal steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal steroids (budesonide or mometasone furoate, 100 μg twice daily for 6 months) starting 2 weeks postoperatively.
Trial: 31418855
Drug: 25 milligrams
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 milligrams cobalt intravenously as CoCl2 weekly
Trial: 31418855
Drug: 50 milligrams
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 milligrams cobalt intravenously as CoCl2 weekly
Trial: 31418855
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cobalt administration)
Trial: 26082975
Drug: Albu‐BChE (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albu‐BChE (50, 100, and 300 mg)
Trial: 16756038
Drug: Intracutaneous injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous injections of 0.1 mL sterile water (n = 25)
Trial: 10780760
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone dipropionate (1.5 mg daily)
Trial: 7693425
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy consisting of fluorouracil, epirubicin plus cyclophosphamide (FEC) for 6 cycles
Trial: 31927162
Drug: Motivational Interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Interviewing plus Cognitive Behavior Therapy (MI/CBT)
Trial: 30195996
Drug: Intermittent sulfadoxine‐pyrimethamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent sulfadoxine‐pyrimethamine (two doses of 1500 mg sulfadoxine and 75 mg pyrimethamine, 4 weeks apart)
Trial: 30195996
Drug: Intermittent chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent chloroquine (two doses of 600 mg on day 1, 600 mg on day 2, and 300 mg on day 3)
Trial: 30195996
Drug: Chloroquine prophylaxis
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine prophylaxis (600 mg on day 1 then 300 mg every week)
Trial: 26276501
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg HDC
Trial: 26276501
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg HDC
Trial: 23855761
Drug: Tofacitinib 2
RxNorm normalized name: tofacitinib 22 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 2 mg
Trial: 16962881
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg and 80 mg (combined analysis)
Trial: 15290426
Drug: Plantar-calf sequential
RxNorm normalized name: thymus gland-calf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plantar-calf sequential compression device
Trial: 11426356
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia with intravenous morphine (n = 15)
Trial: 7868100
Drug: Postpartum monitoring
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postpartum monitoring plus medication (either previously effective medication or nortriptyline)
Trial: 2508567
Drug: Regimen C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen C: MMC 12 mg/m2 i.v. at operation day and 6 mg/m2 in every 2 months + UFT 600 mg/day p.o.
Trial: 2508567
Drug: Regimen D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen D: MMC 12 mg/m2 i.v. at operation day and 6 mg/m2 in every 2 months + UFT 400 mg/day p.o.
Trial: 789082
Drug: Propranolol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (up to 480 mg daily)
Trial: 789082
Drug: Atenolol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (up to 600 mg daily)
Trial: 31264764
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (LY2963016)
Trial: 24133024
Drug: Artificial tears
RxNorm normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial tears (0.1% sodium hyaluronate solution, five times daily)
Trial: 16443860
Drug: Nicorandil (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (12 mg intravenously before reperfusion)
Trial: 10804076
Drug: Regular doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular doses of nortriptyline (60 mg-80 mg/day)
Trial: 10804076
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of nortriptyline (10 mg-13 mg/day)
Trial: 8960488
Drug: Intraligamental injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraligamental injection
Trial: 8507417
Drug: Cotrimoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (160 mg trimethoprim and 800 mg sulphamethoxazole) twice a day on Mondays, Wednesdays and Fridays (n = 81)
Trial: 8507417
Drug: Dapsone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone (100 mg) plus pyrimethamine (25 mg) once a week (n = 85)
Trial: 28731885
Drug: Sleeper stretch
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleeper stretch daily for 8 weeks
Trial: 24403477
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (30 mg of elemental zinc/day for eight weeks)
Trial: 21383341
Drug: Effervescent ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Effervescent ibuprofen (400 mg)
Trial: 21383341
Drug: Standard ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ibuprofen (Nurofen(®) 2 × 200 mg)
Trial: 12576370
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of epinephrine, 1.5 mg, in 4 mL of 3% saline solution (group 2; n = 27)
Trial: 12576370
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of epinephrine, 1.5 mg, in 4 mL of 0.9% saline solution (group 1; n = 25)
Trial: 8594240
Drug: Zidovudine therapy
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine therapy during pregnancy and/or during labor and delivery
Trial: 8594240
Drug: Zidovudine therapy
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine therapy during gestation
Trial: 8487326
Drug: Methotrexate (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (60 mg/m2) and Fluorouracil (600 mg/m2) (MF)
Trial: 8487326
Drug: Cyclophosphamide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (100 mg/m2) orally on days 1‐14 plus MF (CMF)
Trial: 3031714
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg ACTH 4-10
Trial: 27680029
Drug: Intrauterine 500
RxNorm normalized name: Intrauterine System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine 500 IU hCG in up to 0.5 ml normal saline
Trial: 27680029
Drug: Intrauterine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine 0.5 ml normal saline
Trial: 18217157
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg LD / 75 mg MD
Trial: 15452187
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 40,000 U subcutaneous weekly for 16 weeks
Trial: 15452187
Drug: Nonresponders (irrespective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonresponders (irrespective of treatment arm)
Trial: 10811451
Drug: 131I-MAb-LL2 administered
RxNorm normalized name: iobenguane (131I)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 131I-MAb-LL2 administered in a twice weekly pattern with 20 mg of unlabeled LL2 prior to each dose
Trial: 8897877
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg ondansetron (5‐HT3 antagonist)
Trial: 1808368
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of Self Reinforcement after External-Self Dual Reinforcement (delta SR)
Trial: 1808368
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of External Reinforcement following Dual Reinforcement (delta ER)
Trial: 1808368
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of External-Self Dual Reinforcement (delta ESR)
Trial: 6800270
Drug: Amitriptyline tapering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline tapering and discontinuation (double-blind)
Trial: 6800270
Drug: Amitriptyline tapering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline tapering and discontinuation
Trial: 31351660
Drug: Cligosiban 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cligosiban 400 mg
Trial: 31351660
Drug: Cligosiban 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cligosiban 800 mg
Trial: 31351660
Drug: Cligosiban 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cligosiban 1200 mg
Trial: 28204722
Drug: Tramadol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (100 mg, titrated intravenously)
Trial: 28204722
Drug: Morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10 mg additional)
Trial: 25691036
Drug: Deferasirox treatment
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox treatment for 1 year
Trial: 11475442
Drug: IFN-beta-1a 30
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN-beta-1a 30 mcg
Trial: 11475442
Drug: IFN-beta-1a 60
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN-beta-1a 60 mcg
Trial: 7989637
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg MIF‐1 (Pro‐Leu‐Gly‐NH2)
Trial: 2465562
Drug: Histaglobin-Triplex (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histaglobin-Triplex (combination of histamine and human gammaglobulin)
Trial: 30508293
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL water drink
Trial: 30508293
Drug: 330 mL
RxNorm normalized name: ALCOHOL 247.5 mL in 330 mL EXTRACORPOREAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 330 mL water drink
Trial: 28051800
Drug: Lactulose (30-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (30-120 mL/day)
Trial: 24184427
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural therapy
Trial: 31754063
Drug: Living with
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Living with both biological parents
Trial: 10859283
Drug: abciximab-reteplase 5+5
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: abciximab-reteplase 5+5 U with 60 U/kg heparin
Trial: 10859283
Drug: abciximab-reteplase 5+5
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: abciximab-reteplase 5+5 U with 40 U/kg heparin
Trial: 10859283
Drug: low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose heparin
Trial: 8247594
Drug: Glucomannan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucomannan (1 g twice a day for two months)
Trial: 3756056
Drug: Inhaled nitrous
RxNorm normalized name: nitrous oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitrous oxide with i.v. fentanyl increments
Trial: 27253380
Drug: Medication review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication review intervention
Trial: 20157745
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg raloxifene and 1 microg alfacalcidol (RA)/day
Trial: 18601844
Drug: Single Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Chinese herbal medicine‐based intervention
Trial: 18601844
Drug: Active compound‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active compound‐based TCM drug intervention
Trial: 1378646
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg nomegestrol acetate combined with 17-beta-estradiol by transcutaneous route
Trial: 6389217
Drug: Hydrocortisone 17-butyrate
RxNorm normalized name: Cortisol 17-butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 17-butyrate (Locoid) 0.1% cream